

DAFTAR PUSTAKA

- Alice T Shaw, M. P. 2018. Anaplastic lymphoma kinase (ALK) fusion oncogene positive non-small cell lung cancer. Uptodate.
- Amin, Zulkifli. 2006. Kanker Paru. Dalam: Sudoyo, Aru W dkk. Buku ajar ilmu penyakit dalam. Jilid II. Edisi IV. Jakarta: Departemen ilmu penyakit dalam FKUI. Hal. 1005-11
- Amin, Zulkifli. 2014. Kanker Paru. Dalam: Sudoyo, Aru W dkk. Buku ajar ilmu penyakit dalam. Jilid II. Edisi VI. Jakarta: Departemen ilmu penyakit dalam FKUI. Hal. 2998-3007
- Barbara Legius, Sandra Van Den Broecke, Inge Muylle, Vincent Ninane. (2016). Driver oncogenes in Sub-Saharan African patients with NSCLC. *Dovepress*.
- Chia, P. L., Paul, M., Dobrovic, A., & Jhon, T. (2014). Prevalence and natural history of ALK positive non-small-cell lung cancer and the clinical impact of targeted therapy with ALK inhibitors. *Clinical Epidemiology*.
- David R. Hout, Brock L. Schweitzer, Kasey Lawrence, Stephan W. Morris, Tracy Tucker. 2017. Performance of a RT-PCR Assay in Comparison to FISH and IHC for Detection of ALK in NSCLC. *Cancers*.
- Fei Zhou, Caicun Zhou. 2018. Lung cancer in never smokers—the East Asian experience. *Translational lung cancer research*.
- Garber K. 2010. ALK, lung cancer, and personalized therapy: portent of the future? *J Natl Cancer Inst*;102:672–675
- Heng Fan *et al.* 2015. Incidence and survival of non-small cell lung cancer in Shanghai: a population-based cohort study. *British Medical Journal*.
- Ilya Tsimafeyeu, M., Fedor Moiseenko, M., Sergei Orlov, M., Elena Filippova, M., & Alexander Belonogov, M. (2019). Overall Survival of Patients With ALK-Positive. *J Global Oncol.* © 2019 by American Society of Clinical Oncology.
- Ishikawa, K. I. 2016. MicroRNA In Lung Cancer: Novel Biomarkers and. *Journal of Clinical Medicine*.
- June Koo Lee, M., Heae Surng Park, M., Dong-Wan Kim, M. P., Kimary Kulig, P., & Tae Min Kim, M. 2011. Comparative Analyses of Overall Survival in Patients With Anaplastic Lymphoma Kinase-Positive and Matched Wild-Type Advanced Nonsmall Cell Lung Cancer. *Wiley Online*.
- Luis Miguel Seijo Maceiras, Elena Cabezas, Teresa Perez-Warnisher, Manuel Domine, Mabel Cedeño, Federico Rojo. 2017. Prevalence of ALK translocations in a large cohort of non-small cell cancer patients and quality of hybridization by sampling method. *European Respiratory Journal*.
- Lynne Eldridge, M. 2018. ALK Positive Lung Cancer Definition and Treatment. Verywell Health.
- Markman, M. 2017. Genetics of NonSmall. <https://emedicine.medscape.com/article/1689988overview>.

- Pershagen G, Akerblom G, Axelson O, Clavensjo B, Damber L, Desai G, Enflo A, Lagarde F, Mellander H, Svartengren M, *et al.* 2001. Residential radon exposure and lung cancer in Sweden. *N Engl J Med* 2; 330:159-164.
- Kayaniyil, S., Hurry, M., Wilson, J., Wheatley-Price, P., Melosky, B., Rothenstein, J., *et al.* 2016. Treatment patterns and survival in patients with ALK-positive non-small-cell lung cancer: a Canadian retrospective study. *current oncology*.
- Mano, H. (2008-09). Lung: Non-small cell carcinoma with inv(2)(p21p23) EML4/ALK. *Atlas of Genetics and Cytogenetics in Oncology and Haematology*.
- Qiongqiong Gao, Pupu Li, Xiangli Jiang, Zhongli Zhan, Qingna Yan, Bo Zhang and Chun Huang. 2017. Worse disease-free, tumor-specific, and overall survival in surgically-resected lung adenocarcinoma patients with ALK rearrangement. *Oncotarget*.
- Silvestri GA, Tanoue LT, Margolis ML, Barker J, Detterbeck F: *The noninvasive staging of non-small cell lung cancer. The guidelines.* *Chest.* 123: 2003; 147S-156S
- Van Cleemput J, De Raeve H, Verschakelen JA, Rombouts J, Lacquet LM, Nemery B. 2001. Surface of localized pleural plaques quantitated by computed tomography scanning: no relation with cumulative asbestos exposure and no effect on lung function. *Am J Respir Crit Care Med*; 163:705-710